Stryker Co. (NYSE:SYK) Shares Acquired by Axa S.A.

AXA S.A. lifted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 12.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 128,242 shares of the medical technology company's stock after purchasing an additional 13,775 shares during the quarter. AXA S.A.'s holdings in Stryker were worth $46,174,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Stryker by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after purchasing an additional 252,188 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Stryker by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after purchasing an additional 54,693 shares during the period. FMR LLC increased its position in Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after purchasing an additional 727,850 shares in the last quarter. Geode Capital Management LLC lifted its position in Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after buying an additional 168,436 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Stryker in the fourth quarter worth $1,710,744,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on SYK shares. Truist Financial lifted their target price on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a report on Monday. The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Canaccord Genuity Group raised their target price on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Monday. Finally, Stifel Nicolaus lifted their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average price target of $427.05.

Stryker Stock Up 1.7 %

NYSE SYK traded up $6.32 on Wednesday, hitting $383.84. 1,196,082 shares of the stock traded hands, compared to its average volume of 1,357,745. The company has a market capitalization of $146.51 billion, a P/E ratio of 49.46, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The stock has a 50-day moving average of $365.95 and a 200 day moving average of $374.03. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same period last year, the business posted $2.50 earnings per share. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. As a group, analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.